The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.